Top

Published in:

01-12-2015 | Research Article

Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen

Authors: Ping Li, Ya-Di Wang, Jian Cheng, Jun-Chen Chen, Min-Wen Ha

Published in: Tumor Biology | Issue 12/2015

Abstract

BCL-2 Associated athanogene 1 (BAG-1) and Xeroderma pigmentosum group D (XPD) are involved in the nucleotide excision repair pathway and DNA repair. We aimed to investigate whether polymorphisms in BAG-1 and XPD have effects on chemotherapy sensitivity and survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with vinorelbine combined cisplatin (NP) regimen. A total of 142 patients with diagnosed advanced NSCLC were recruited in the current study. NP regimen was applied for all eligible patients. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used for BAG-1 (codon 324) and XPD (codons 312 and 751) genotyping. The treatment response was evaluated according to the RECIST guidelines. Progression-free survival (PFS) and overall survival (OS) were record as median and end point, respectively. As for BAG-1 codon 324, the chemotherapy sensitivity in NSCLC patients with CT genotype was 0.383 times of those with CC genotype (P < 0.05). With respect to XPD codon 751, the chemotherapy sensitivity in NSCLC patients with Lys/Gln genotype was 0.400 times of those with Lys/Lys genotype (P < 0.05). In addition, NSCLC patients carrying combined C/C genotype at codon 324 in BAG-1, Asp/Asp of XPD codon 312, and Lys/Lys of XPD codon 751 produced a higher efficacy of NP chemotherapy compared to those carrying mutation genotypes (all P < 0.05). Further, there were significant differences in PFS between patients with combined C/C genotype of BAG-1 codon 324, Lys/Lys genotype of XPD codon 751, and Asp/Asp genotype of XPD codon 312 and patients carrying BAG-1 codon 324 C/T genotype, XPD codon751 Lys/Gln genotype, and XPD codon312 Asp/Asn genotype (P < 0.05). Multivariate Cox regression analysis indicated that the combined wild-type of codon 324 XPD, codon 751 XPD, and codon 312 BAG-1 is the protective factor for OS and PFS, and clinical stages is the risk factor for OS and PFS. In conclusion, our research demonstrated the combined effects of BAG-1 and XPD polymorphisms on chemotherapy sensitivity and survival in patients with advanced NSCLC, which might be the important predictive markers for platinum-based chemotherapy efficacy.

Xie KJ, He HE, Sun AJ, Liu XB, Sun LP, Dong XJ. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy. Asian Pac J Cancer Prev. 2014;15(6):2591–6.CrossRefPubMed

Cortes R, Tarrado-Castellarnau M, Talancon D, Lopez C, Link W, Ruiz D, et al. A novel cyclometallated Pt(II)-ferrocene complex induces nuclear FOXO3a localization and apoptosis and synergizes with cisplatin to inhibit lung cancer cell proliferation. Metallomics. 2014;6(3):622–33.CrossRefPubMed

Lima A, Seabra V, Martins S, Coelho A, Araujo A, Medeiros R. Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Mol Biol Rep. 2014;41(5):3349–57.CrossRefPubMed

Zhou Y, Pan DS, Shan S, Zhu JZ, Zhang K, Yue XP, et al. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in non-small-cell lung cancer cells. Biomed Pharmacother. 2014;68(4):483–91.CrossRefPubMed

Reinmuth N, Meyer A, Hartwigsen D, Schaeper C, Huebner G, Skock-Lober R, et al. Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIb/IV non-small cell lung cancer (NSCLC). Lung Cancer. 2014;83(3):363–8.CrossRefPubMed

Chang WJ, Sun JM, Lee JY, Ahn JS, Ahn MJ, Park K. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin. Lung Cancer. 2014;84(1):51–5.CrossRefPubMed

Bennouna J, Havel L, Krzakowski M, Kollmeier J, Gervais R, Dansin E, et al. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an international randomized phase II study (NAVotrial 01). Clin Lung Cancer. 2014;15(4):258–65.CrossRefPubMed

Chen LK, Liang Y, Yang QY, Xu F, Zhou NN, Xu GC, et al. Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev. 2012;13(5):1863–7.CrossRefPubMed

Du Y, Su T, Zhao L, Tan X, Chang W, Zhang H, et al. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer. PLoS One. 2014;9(6), e99843.CrossRefPubMedPubMedCentral

10.

Wang YD, Ha MW, Cheng J, Zhang WL, Cong X, Tong CY, et al. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC. Oncol Rep. 2012;27(4):979–86.PubMed

11.

Liman J, Faida L, Dohm CP, Reed JC, Bahr M, Kermer P. Subcellular distribution affects BAG1 function. Brain Res. 2008;1198:21–6.CrossRefPubMed

12.

Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, et al. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell. 1995;80(2):279–84.CrossRefPubMed

13.

Leng XF, Chen MW, Xian L, Dai L, Ma GY, Li MH. Combined analysis of mrna expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy. J Exp Clin Cancer Res. 2012;31:25.CrossRefPubMedPubMedCentral

14.

Qiu M, Yang X, Hu J, Ding X, Jiang F, Yin R, et al. Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2013;8(8), e72251.CrossRefPubMedPubMedCentral

15.

Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009;27(21):3540–6.CrossRefPubMedPubMedCentral

16.

Wu W, Li H, Wang H, Zhao X, Gao Z, Qiao R, et al. Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for chinese non-small cell lung cancer patients. PLoS One. 2012;7(3), e33200.CrossRefPubMedPubMedCentral

17.

Mathiaux J, Le Morvan V, Pulido M, Jougon J, Begueret H, Robert J. Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer. Mol Diagn Ther. 2011;15(3):159–66.CrossRefPubMed

18.

Yang Y, Xian L. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol. 2014;35(4):2905–21.CrossRefPubMed

19.

Wu W, Zhang W, Qiao R, Chen D, Wang H, Wang Y, et al. Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a chinese population. Clin Cancer Res. 2009;15(11):3889–95.CrossRefPubMed

20.

The Helsinki Declaration of the World Medical Association (WMA). Ethical principles of medical research involving human subjects. Pol Merkur Lekarski. 2014;36(215):298–301.

21.

Mor V, Laliberte L, Morris JN, Wiemann M. The karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer. 1984;53(9):2002–7.CrossRefPubMed

22.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed

23.

Liu H, Liang Y, Li Y, Li Y, Wang J, Wu H, et al. Gene silencing of BAG-1 modulates apoptotic genes and sensitizes lung cancer cell lines to cisplatin-induced apoptosis. Cancer Biol Ther. 2010;9(10):832–40.CrossRefPubMed

24.

Clemo NK, Collard TJ, Southern SL, Edwards KD, Moorghen M, Packham G, et al. BAG-1 is up-regulated in colorectal tumour progression and promotes colorectal tumour cell survival through increased NF-kappaB activity. Carcinogenesis. 2008;29(4):849–57.CrossRefPubMed

25.

Zhan P, Wang Q, Wei SZ, Wang J, Qian Q, Yu LK, et al. ERCC2/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case–control studies. J Thorac Oncol. 2010;5(9):1337–45.CrossRefPubMed

26.

Qiu LX, Yao L, Zhang J, Zhu XD, Zhao XM, Xue K, et al. XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects. Breast Cancer Res Treat. 2010;124(1):229–35.CrossRefPubMed

27.

Avan A, Pacetti P, Reni M, Milella M, Vasile E, Mambrini A, et al. Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Int J Cancer. 2013;133(4):1016–22.CrossRefPubMed

28.

Giovannetti E, Pacetti P, Reni M, Leon LG, Mambrini A, Vasile E, et al. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics. 2011;12(12):1641–52.CrossRefPubMed

29.

McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J, Wysoker A, et al. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet. 2008;40(10):1166–74.CrossRefPubMed

30.

Li J, Das K, Fu G, Li R, Wu R. The Bayesian lasso for genome-wide association studies. Bioinformatics. 2011;27(4):516–23.CrossRefPubMed

31.

Hoggart CJ, Whittaker JC, De Iorio M, Balding DJ. Simultaneous analysis of all SNPs in genome-wide and re-sequencing association studies. PLoS Genet. 2008;4(7), e1000130.CrossRefPubMedPubMedCentral

Title: Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen
Authors: Ping Li
Ya-Di Wang
Jian Cheng
Jun-Chen Chen
Min-Wen Ha
Publication date: 01-12-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3672-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2015

Resveratrol induces AMPK-dependent MDR1 inhibition in colorectal cancer HCT116/L-OHP cells by preventing activation of NF-κB signaling and suppressing cAMP-responsive element transcriptional activity

TLR2∆22 (-196-174) significantly increases the risk of breast cancer in females carrying proline allele at codon 72 of TP53 gene: a case–control study from four ethnic groups of North Eastern region of India

Functional significance of macrophages in pancreatic cancer biology

The possible role of EZH2 and DNMT1 polymorphisms in sporadic triple-negative breast carcinoma in southern Chinese females

Influence of functional polymorphisms in TNF-α, IL-8, and IL-10 cytokine genes on mRNA expression levels and risk of gastric cancer

Autoantibodies to chromogranin A are potential diagnostic biomarkers for non-small cell lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer